Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456399 | 0.87 | ME2 (0.47) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL30010609 | 0.81 | RET (0.51) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL21855212 | 0.79 | MAPT (0.60) | ALDH1A1HPGDCYP2C9MAPK1CYP1A2 | |
| SCHEMBL4763473 | 0.78 | KMT2A (0.62) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL21855140 | 0.78 | USP2 (0.56) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL15638362 | 0.77 | GRIN2D (0.43) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL4069836 | 0.76 | HDAC1 (0.72) | KCNH2HDAC1 | |
| SCHEMBL3539822 | 0.76 | CYP3A4 (0.41) | HSD17B10ALDH1A1HPGDCYP3A4GRIN2D | |
| SCHEMBL15652304 | 0.76 | SYK (0.48) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15636048 | 0.75 | GRIN2D (0.44) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | HSD17B10 3716/4885ALDH1A1 4160/4885HPGD 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.